Georgios D.
- Country
- Greece
- Department
- Ηigh Dependency Unit of Department of Clinical Therapeutics
Research Overview
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of OMN6 in Patients with Acinetobacter baumannii Complex-Induced HABP or VABP
- Adjunctive Clarithromycin to Prevent Secondary Infections in Patients with Community‑Acquired Pneumonia‑Related Sepsis and Sepsis‑Induced Immunoparalysis (CLASSIFY)
- Evaluation of Emapalumab in Patients with Interferon-Gamma Driven Sepsis: A Randomized, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 15 of 29 partner sites.
Specializations
Critical Care Medicine
The investigator specializes in the study and treatment of severe sepsis, with particular focus on understanding and addressing specific disease endotypes that influence patient outcomes.
- Sepsis immunotherapy
- Interferon-gamma pathways
- Endotype-driven treatment approaches
Their research explores innovative therapeutic interventions in critical care settings, particularly focusing on monoclonal antibody treatments for sepsis management.
Immunology
The investigator concentrates on understanding immune system modulation in severe infections, with specific attention to the role of cytokines in disease progression.
- Cytokine-targeted therapies
- Immune response patterns
- Biomarker identification
Their work examines the therapeutic potential of targeted immunological interventions in critical illness.
Personalized Medicine
The investigator focuses on developing patient-specific treatment strategies based on individual immunological profiles and disease characteristics.
- Endotype-based patient stratification
- Treatment optimization
- Therapeutic monitoring
Their research aims to advance precision medicine approaches in critical care settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.